Navigation Links
Perrigo Company Announces Final FDA Approval for OTC Famotidine Complete Chewable Tablets
Date:2/12/2008

ALLEGAN, Mich., Feb. 12 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for over-the-counter Famotidine 10 mg, Calcium Carbonate 800 mg, and Magnesium Hydroxide 165 mg, Chewable Tablets.

The product will be marketed under store brand labels and is comparable to Johnson & Johnson - Merck Consumer Pharmaceutical's Pepcid(R) Complete, an acid reducer plus antacid medication indicated for the relief of heartburn associated with acid indigestion and sour stomach. Annual retail sales for Pepcid Complete chewable tablets are estimated to be approximately $95 million.

Perrigo's Chairman and CEO Joseph C. Papa concluded, "This final approval reflects our continuing investment in new products. As always, Perrigo is committed to making quality healthcare more affordable for our customers and drive value for our shareholders."

Perrigo was the first applicant to file a complete ANDA with a Paragraph IV certification and we expect to have marketing exclusivity. The Company expects to begin shipping the product in the third quarter of calendar 2008.

Perrigo Company is a leading global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription pharmaceuticals, nutritional products, active pharmaceutical ingredients (API) and consumer products. The Company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market. The Company's primary markets and locations of manufacturing facilities are the United States, Israel, Mexico and the United Kingdom. Visit Perrigo on the Internet (

SOURCE Perrigo Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Perrigo Vice Chair Mori Arkin To Retire After 30 Years of Service
2. Perrigo Company to Host Analyst Meeting on September 18, 2007
3. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
4. Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution
5. Perrigo Confirms Filing for Generic Version of Mucinex(R) and Announcement of Lawsuit by Adams Respiratory
6. Perrigo Company Will Release First Quarter Fiscal 2008 Results on November 1, 2007
7. Perrigo Company Announces Dividend Increase
8. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
9. Perrigo Company to Present at The 26th Annual JPMorgan Healthcare Conference
10. Perrigo Acquires UK OTC Store Brand Supplier
11. Perrigo Company Authorizes Continuation of Share Repurchase Program and Announces Quarterly Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... (PRWEB) May 29, 2015 The science ... in Los Angeles thanks to the efforts of internationally ... Mohebi has combined ARTAS hair restoration and ... hair restoration procedures available anywhere. , A Follicular ... and individually harvesting hair follicle grafts from the donor ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 John A. ... to Cincinnati , The Department of Veterans Affairs (VA) ... Gennaro as the new director of the Cincinnati VA ... care to more than 43,000 unique Veterans annually and ... over 2,000 staff, CVAMC is a two-division campus located ...
(Date:5/29/2015)... The science of Follicular Unit Extraction ... and more efficient methods of FUE hair transplantation have increased ... of the most cutting edge hair transplant methods being used ... technique of extracting hair from the beard to the scalp. ... to correct male pattern baldness. Beard hair has a ...
(Date:5/29/2015)... On May 21, 2015, Elle Magazine in article titled ... Botox ?” reported on the four most commonly searched beauty ... to determine these results and then sought expert help to ... example, is how to keep neck skin tight . ... the appropriate age to start receiving Botox injections . ...
(Date:5/29/2015)... To compile the list, the Becker's Hospital ... several awards for clinical and general excellence. The team ... to them in terms of overall excellence, and those ... 50 Great Health Systems to Know 2015 list includes ... Fla.) , Advocate Health Care (Downers Grove, Ill.) , ...
Breaking Medicine News(10 mins):Health News:Los Angeles and Beverly Hills Hair Transplant Doctor Now Combines Robotic Hair Restoration (ARTAS) and Manual FUE Transplants for Maximum Hair Coverage 2Health News:VA Healthcare System of Ohio Network Announces New Medical Center Director 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Botox, Wrinkles and Double Chins: The Most-Asked Beauty Problems According to Google 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 2Health News:Becker's Hospital Review Names 50 Great Health Systems to Know 3
... improves patient satisfaction scores, ATLANTA, Jan. ... effectively,measure individual performance and improve patient satisfaction ... patient,satisfaction benchmarks established through Press Ganey with ... score by 2 points within 24,months. In ...
... Jan. 25 Super Bowl Sunday,s almost here-and,what better ... healthy,and losing some weight. Right? As more than 90 ... biggest event of the year, we,plan parties predicting the ... With those big-guy pro,s gearing up for Super ...
... in Belgium have significantly advanced the discovery of a ... insulin-producing beta cells. If the finding made in mice ... an obvious target for therapeutic regeneration of beta cells ... issue of the research journal Cell, a publication of ...
... LOS ANGELES, Jan. 25 An unprecedented move,by residential ... came to the table to settle two class action ... 21, 2007 in Orange,County Superior Court, and one in ... Multnomah County Circuit Court and,should receive final approval in ...
... ALEXANDRIA, Va., Jan. 25 - In a speech,earlier ... revealed the,company was in the initial stages of ... RPh, executive vice president and CEO,of the National ... "The PBM industry badly needs to be reformed. ...
... Patients who got calls from those who had ... , , FRIDAY, Jan. 25 (HealthDay News) -- Patients who ... to undergo the screening for colorectal cancer, say University ... that people who received telephone mentoring from a trained ...
Cached Medicine News:Health News:Emory Healthcare Uses SciHealth to Improve Patient Satisfaction 2Health News:Super Bowl and SuperFoods: Play Smart 2Health News:Elusive pancreatic progenitor cells found in mice 2Health News:Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit 2Health News:Elder Care Operator and Plaintiff Attorney Announce Unprecedented Settlement Agreement in Class Action Lawsuit 3Health News:NCPA Statement on Wal-Mart's Entry Into the Pharmacy Benefit Market 2Health News:Colonoscopy 'Coaches' Play Lifesaving Role 2
(Date:5/29/2015)... 2015 Amgen (NASDAQ: AMGN ) ... 3, global, randomized, placebo-controlled trials evaluating AMG 416, ... hyperparathyroidism (SHPT) in patients with chronic kidney disease ... endpoint, demonstrating that a greater proportion of patients ... than 30 percent reduction in parathyroid hormone (PTH) ...
(Date:5/28/2015)... 2015  Eli Lilly and Company (NYSE: LLY ) ... tender offer for up to $1.6 billion aggregate principal amount ... of notes who tendered, and did not validly withdraw, their ... City time, on May 27, 2015 (the early ... are eligible to receive the total consideration. The total consideration ...
(Date:5/28/2015)... YORK , May 28, 2015 /PRNewswire/ ... developing new drugs and tests, and this ... the instruments that can assist them. This according ... publisher. Kalorama Information said instruments such as mass ... assist in the identification of drug targets ...
Breaking Medicine Technology:Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 2Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 3Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 4Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 5Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 6Amgen Presents Pooled Phase 3 AMG 416 Data For The Treatment Of Secondary Hyperparathyroidism In Patients With Chronic Kidney Disease 7Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3
... , , , ... today announced the presentation of data highlighting the links between medication ... postmenopausal osteoporosis. The data were presented at the 31st annual meeting ... , "These data enhance our understanding of why many ...
... , , , SAN ... of two studies of DAS181 activity against H1N1 influenza and ... and Chemotherapy (ICAAC) meeting on Sunday, September 13, 2009, in ... with researchers at the Centers for Disease Control and Prevention ...
Cached Medicine Technology:Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 2Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 3Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 4Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 5Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 6Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 7Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 8Data Show Medication Adherence is an Important Factor in the Treatment of Postmenopausal Osteoporosis 9NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009 2NexBio(R) Presents DAS181 (Fludase(R)*) Potently Inhibits Novel Swine-Origin A(H1N1) and NAI-Resistant Influenza Viruses, at ICAAC 2009 3
Sterile squares of smooth foil for repair of the floor of the orbit and other plastic surgery. Available in large size....
Clear Base Stand Magnifiers are ideal for any visual task that requires high magnification....
Bausch & Lomb magnifiers incorporates precision optics and patented ergonomic designs for increased clarity and comfort during use....
Ultra Thin Sheet. Medpor Sheets are commonly used for orbital floor reconstruction and other craniofacial applications....
Medicine Products: